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Abstract
The slow progression of early age-related macular degen-
eration (AMD) stages to advanced AMD requires the use of 
surrogate end points in clinical trials. The use of combined 
end points may allow for shorter and smaller trials due to in-
creased precision. We performed a literature search for the 
use of composite end points as primary outcome measures 
in clinical studies of early AMD stages. PubMed was searched 
for composite end points used in early/intermediate AMD 
studies published during the last 10 years. A total of 673 ar-
ticles of interest were identified. After reviewing abstracts 
and applicable full-text articles, 33 articles were eligible and 
thus included in the qualitative synthesis. The main compos-
ite end point categories were: combined structural and func-
tional end points, combined structural end points, com-
bined functional end points and combined multicategorical 
end points. The majority of the studies included binary com-
posite end points. There was a lack of sensitivity analyses of 
different end points against accepted outcomes (i.e., pro-
gression) in the literature. Various composite outcome mea-
sures have been used but there is a lack of standardization. 
To date no agreement on the optimal approach to imple-
ment combined end points in clinical studies of early stages 
of AMD exists, and no surrogate end points have been ac-
cepted for AMD progression. © 2020 The Author(s)
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Age-related macular degeneration (AMD) is one of 
the major causes of visual loss in the elderly worldwide, 
impairing physical, emotional and social well-being of 
those affected [1–3]. Due to population aging, patient 
numbers are expected to increase significantly over the 
next decades [4, 5]. While people with early stages of 
AMD are often asymptomatic under everyday lighting 
conditions, individuals with advanced AMD may develop 
irreversible central scotoma due to atrophy of outer reti-
nal layers or choroidal neovascularization [2, 6, 7]. At 
present, therapies are only available for neovascular 
AMD. However, new therapies preventing nonadvanced 
disease from progressing are required to reduce the glob-
al burden of blindness due to AMD.
No clinical trial end points have been developed for 
this indication yet. In neovascular AMD trials, high lumi-
nance high contrast best-corrected visual acuity (BCVA) 
is an end point accepted by the regulatory authorities but 
BCVA is not sensitive enough to measure the functional 
deficit specific to early and intermediate AMD. Those are 
stages in which BCVA is largely unaffected but the visual 
deficit is prominent under low luminance or low contrast 
conditions [6, 7]. Progression from early AMD stages to 
advanced AMD is a slow process [8]. Thus, new surrogate 
end points for the progression of early and intermediate 
AMD to advanced AMD are needed [9].
Various end points, including structural, functional 
and patient-reported variables, have been implemented 
in previous studies of early AMD stages [10–19]. Com-
posite end points summarize single end points across 
these different categories, increasing the overall sensitiv-
ity of the end point for reaching accepted outcomes (i.e., 
progression). If used in clinical trials, more sensitive com-
posite end points would thus allow for smaller and short-
er trials to be performed, without a reduction in statistical 
power [20, 21]. Sophisticated composite end points have 
been proposed for longitudinal studies in glaucoma but 
their relevance to current AMD research is unclear [22]. 
In order to assess the current state of relevant available 
research we reviewed the literature for the use of compos-
ite end points as primary outcome measures in clinical 
studies of early AMD stages.
Methods
PubMed was searched in August 2020 using the following 
search terms: age-related macular degeneration, early, intermedi-
ate, nonexudative, nonadvanced, Age-Related Eye Disease Study 
(AREDS) 2/3, end point, outcome and biomarker. All relevant ab-
stracts were reviewed, and full-text articles were downloaded when 
indicated. Inclusion criteria were interventional or longitudinal 
studies on early or intermediate AMD including primary compos-
ite end points. Only studies published within the last 10 years were 
considered. Exclusion criteria were articles dealing primarily with 
neovascular AMD, geographic atrophy or diseases other than 
AMD, articles focusing mainly on serum biomarkers as well as ar-
ticles in languages other than English.
Results
Our initial search yielded a total of 673 articles of inter-
est. After screening the abstracts, 601 articles did not meet 
the inclusion criteria and were therefore excluded. We 
thus assessed 72 full-text articles for eligibility. Thirty-
nine of these articles were excluded based on full-text as-
sessment. Reasons for exclusion were: 25 studies did not 
implement composite end points, 4 investigated a healthy 
cohort, 3 were cross-sectional studies, 2 included partici-
pants with only late AMD, 2 were reviews, 1 was focused 
on serum biomarkers, 1 was focused on device-related 
instead of disease-related outcomes, 1 investigated single 
cases only. Thus, we included 33 articles in the qualitative 
synthesis. Twenty-two of these articles were published 
between 2016 and 2020 while 11 articles were published 
between 2010 and 2015.
Combined Structural and Functional Outcomes
Our search revealed 8 articles (7 studies) that imple-
mented combinations of structural and functional out-
come measures (Table 1); 4 of the studies were interven-
tional [10–15, 19, 23]. Chew et al. [10, 12] combined fun-
dus photography-based structural outcome measures 
providing evidence of progression to late AMD with BCVA 
loss in follow-up reports of the AREDS. Nittala et al. [14] 
combined thickness assessment of the retinal pigment epi-
thelium (RPE)-drusen complex on optical coherence to-
mography and low luminance visual acuity in a longitudi-
nal cohort study of 85 fellow eyes of neovascular AMD 
eyes. Robinson et al. [13] used onset of late AMD, increase 
in drusen volume and changes in the cone time constant in 
adaptometry as primary co-outcome measures in a ran-
domized trial of light therapy with 60 participants [23]. 
Guymer et al. [11] investigated the primary outcome mea-
sures BCVA, drusen area and macular sensitivity on flick-
er perimetry in a pilot trial on nanosecond laser therapy 
with 50 participants. Recently, Saßmannshausen et al. [15] 
investigated point-wise sensitivity changes and retinal 
thickness changes as main outcome measures in a longitu-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































dinal study of 54 patients with intermediate AMD and in 
25 patients with intermediate AMD and predominantly 
subretinal drusenoid deposits [19].
Combined Structural Outcomes
We identified 20 articles focusing on combined struc-
tural outcome measures (Table 1), 3 of which were inter-
ventional [17, 18, 24–41]. Twelve of these 20 articles in-
cluded progression to late-stage AMD (development of 
choroidal neovascularization or geographic atrophy) as a 
composite end point [25–27, 29, 31, 33–36, 38–40]. Four 
of the articles reported the use of specific severity scales 
based on the anatomical AMD classification and imple-
menting an additive structure (including increased dru-
sen size and/or pigmentation as well as progression to late 
AMD) as the main outcome measure [24, 28, 30, 32]. Four 
other reports combined structural outcome measures dif-
ferent from the ones described. Wu et al. [17] defined 2 
optical coherence tomography-based biomarkers (sub-
sidence of the outer plexiform layer and inner nuclear 
layer and development of a hyporeflective wedge-shaped 
band within the limits of the outer plexiform layer) and 
combined them to the outcome measure “nascent geo-
graphic atrophy” in their analysis of 181 participants. 
Veerappan et al. [18] used a set of pre-atrophic findings 
(including RPE-drusen complex thinning, RPE disrup-
tion, photoreceptor layer thinning) and progression to 
late-stage AMD as primary outcome measures in their 
analysis of 349 participants of the ARED Study 2 ancillary 
spectral-domain optical coherence tomography study. 
Alexandre de Amorim Garcia Filho et al. [37] combined 
progression to late AMD with changes of the area of pig-
ment epithelial detachments on optical coherence to-
mography to a main outcome measure. Kim et al. [41] 
combined drusen area on fundus photography and pig-
ment epithelial detachment height on optical coherence 
tomography as primary co-outcomes.
Combined Functional Outcomes
Two studies combined different functional outcomes 
(Table 1). Wu et al. [6] described pointwise sensitivities 
obtained from fundus-controlled perimetry (micrope-
rimetry) as well as low luminance visual acuity (LLVA) in 
a longitudinal study of 49 participants with nonadvanced 
AMD. Hsu et al. [42] investigated several functional end 
points (BCVA, LLVA, low luminance deficit, percent-re-
duced threshold and average threshold from fundus-con-
trolled perimetry as well as cone contrast tests) in 85 par-
ticipants with early/intermediate AMD and healthy con-
trol participants longitudinally.
Combined Multicategorical Outcomes
In addition, we identified 3 reports that included end 
points from more than 1 of the outcome categories men-
tioned above (Table 1). Two reports described the MA-
CUSTAR study, a longitudinal study validating various 
functional, structural and patient-reported outcome 
measures in a large cohort of intermediate AMD patients 
which is still ongoing [43, 44].
Curcio et al. [45] described the use of various out-
comes (obtained from rod-mediated dark adaptation, 
2-color dark-adapted microperimetry, light-adapted pe-
rimetry, photopic acuity, mesopic acuity, photopic con-
trast sensitivity, mesopic contrast sensitivity, color fun-
dus photography, near-infrared reflectance, optical co-
herence tomography angiography, quantitative 
autofluorescence, low luminance questionnaire, Vision 
in Low Luminance questionnaire and other assessments) 
in the Alabama Study on Early Age-Related Macular De-
generation 2 (ALSTAR2) which is also ongoing.
Sensitivity of Composite End Points
None of the articles compared sensitivities of single 
end points for reaching accepted outcomes to sensitivities 
of composite end points.
Discussion
Several variations of combined outcome measures and 
composite end points have been used in clinical studies of 
early and intermediate AMD. The most frequent combi-
nations were those of various structural end points, fol-
lowed by combinations of structural and functional end 
points. However, no structural clinical trial end point ex-
cept the relatively rare event of progression to advanced 
neovascular or atrophic AMD is currently accepted by 
regulatory authorities and health technology assessment 
bodies [43]. Due to increasing numbers of patients with 
AMD, new therapies are urgently required and for this, 
validated end points are a prerequisite to enable future 
therapeutic developments [4].
In the 2017 National Eye Institute/United States Food 
and Drug Administration end point workshop on AMD, 
the potential benefit of using surrogate end points as pre-
dictors of a clinically meaningful outcome (such as pho-
toreceptor loss) was highlighted [7]. We have identified 
several combined AMD outcome measures used as sur-
rogates for the loss of photoreceptors reported in the lit-
erature. The majority are simple binary outcome mea-
sures indicating that a catalogue of single yes- or no-type 
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end points are combined [20, 21]. Usually, the overall end 
point is reached when at least one of the single end points 
is reached (Boolean OR operator). An example used by 
many of the studies identified in our review is conversion 
to late AMD which includes the single end points “con-
version to neovascular AMD” and “conversion to geo-
graphic atrophy” [25–27, 29, 39, 46]. This composite end 
point reflects the strong association between vision loss 
and the presence of any advanced disease stage [1, 3] and 
is an accepted end point by regulatory authorities [43]. 
However, due to the relatively slow progression of AMD 
(on average 5–20 events per 100 person-years) and the 
need for shorter trial durations for novel future therapeu-
tics [43, 47], it is unsuitable for studies of early or inter-
mediate AMD. Thus, end points associated with earlier 
AMD disease stages and with a high sensitivity for pro-
gression are required. Progression of classic structural pa-
rameters such as drusen size or hyperpigmentation (and 
their correlates on optical coherence tomography) do not 
show strong enough associations with vision loss to be 
acceptable to regulators [48]. The composite end point 
nascent geographic atrophy appears to be a promising 
predictor of atrophy development, yet it is not associated 
with neovascular AMD and does not include a functional 
dimension, as desired by regulatory agencies [7, 17]. With 
respect to functional end points, BCVA has been shown 
to be insensitive to the deficit specific to early AMD stag-
es and seems to be inappropriate both as a single end 
point and as part of an intermediate AMD-targeted com-
posite end point from what is currently known [6, 7]. 
Other functional variables like LLVA, microperimetry 
and dark adaptometry appear more promising but lack 
data over the long term [6, 11, 13, 15]. In summary, we 
have found different approaches of using binary outcome 
measures in the literature but none seems to be ready for 
use in prospective large-scale clinical trials.
Another potential composite end point category is 
continuous end points which use scores calculated from 
the single end points of different levels of measurement. 
Composite scores have been sparsely used in AMD 
studies to date. However, continuous composite end 
points have a high potential because they allow integra-
tion of different outcome categories and thus can lead 
to an increase in statistical power within treatment 
studies when carefully validated [49]. Sensitivity testing 
and a validation of different composite end points in 
AMD research have yet to be performed which is why 
the MACUSTAR and ALSTAR2 studies as well as the 
AMD Ryan Initiative Study (ARIS) are currently being 
conducted [43–45, 50].
Similarly to composite end points, a variety of single out-
comes have been associated with progression to late-stage 
disease [3, 36, 51–64]. Schaal et al. [65] have published a 
comprehensive review of anatomical end points in nonexu-
dative AMD. Overall, many different composite end points 
are available in the literature, but broader consensus defini-
tions of AMD outcome measures are required [7].
The use of composite end points is also met with inter-
est in other areas of ophthalmology. Due to the absence 
of a gold standard of determining physiological changes 
versus disease progression, glaucoma researchers use sur-
rogate end points regularly including intraocular pres-
sure and certain visual field indices [66]. These single sur-
rogate end points can be combined to composite scores. 
Such composite end points in glaucoma have been dem-
onstrated to increase accuracy of prediction of progres-
sion, reduce measurement variability and require smaller 
sample sizes than single end points derived from, for ex-
ample, perimetry [22, 67]. Similarly, the role of surrogate 
end points as well as composite end points in clinical 
studies of dry eye disease is growing [68, 69]. Specifically, 
various clinical scores are used as end points, enabling the 
development of continuous composite end points [68].
Beyond ophthalmology, composite end points have 
been met with considerable interest in the context of Alz-
heimer’s disease where combined cognitive and function-
al outcome measures have gained in importance over the 
last few years [70]. An analysis of 2 expedited pharmaceu-
tics approval pathways of the European Medicines Agen-
cy across specialities between 2011 and 2018 showed that 
the majority of authorizations was based on surrogate end 
points, and a relevant number of authorizations included 
composite end points [71]. Thus, reliable and valid com-
posite end points are required to enable future therapeu-
tic developments in intermediate AMD, which represent 
a huge unmet need.
The strengths of our work include the systematic review 
of the available literature as well as the data synthesis and 
categorization into different types of composite end points. 
The focused search of only one data base (PubMed) may 
limit generalizability of results and reduce completeness. 
However, a high number of relevant studies can generally 
be expected to be published in journals indexed in PubMed.
In conclusion, the use of composite end points and com-
bined outcome measures in longitudinal and intervention-
al studies of early and intermediate AMD is increasing. Var-
ious composite measures have been used but there is a lack 
of standardization and validation. To date no agreement on 
the best approach to implement combined end points in 
clinical trials of early stages of AMD exists.
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